Literature DB >> 7134628

The use of a new radioactive-iodine labeled lipid marker to follow in vivo disposition of liposomes: comparison with an encapsulated aqueous space marker.

R M Abra, H Schreier, F C Szoka.   

Abstract

The in vivo disposition of multilamellar liposomes extruded at 0.6 micrometers (PC/DPPA/CH/ alpha-T = 4:1:5:0.1 molar ratio) when injected i.v. into mice has been examined utilizing a novel iodinatable phospholipid derivative as a lipid phase marker (p-hydroxybenzamidine phosphatidylethanolamine: 125I-BPE) and compared to that using 14C-inulin as an aqueous phase marker. At times up to 5 h post-dose the disposition of both markers was essentially identical with the exception of blood and intestine, where 125I-BPE levels were consistently higher than 14C-inulin levels. At time intervals from 5-72 h post-dose 125I-BPE levels in all the organs examined were lower than those of 14C-inulin. These differences in the behaviour of the two labels may be explained in terms of exchange of the iodinated lipids, excretion of released inulin and long term metabolism of the lipid marker. We conclude tha 125I-BPE is a useful marker for following liposome disposition in short-term studies particularly in view of the easily quantifiable nature of gamma-radioactivity which obviates the need for sample preparation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7134628

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  9 in total

1.  Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration.

Authors:  Kareen Riviere; Zhaohua Huang; Katherine Jerger; Nichole Macaraeg; Francis C Szoka
Journal:  J Drug Target       Date:  2010-03-30       Impact factor: 5.121

2.  Delivery of therapeutic doses of doxorubicin to the mouse lung using lung-accumulating liposomes proves unsuccessful.

Authors:  R M Abra; C A Hunt; K K Fu; J H Peters
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Efficiency of cytoplasmic delivery by pH-sensitive liposomes to cells in culture.

Authors:  C J Chu; J Dijkstra; M Z Lai; K Hong; F C Szoka
Journal:  Pharm Res       Date:  1990-08       Impact factor: 4.200

4.  Increased efficacy of phosphonoformate and phosphonoacetate inhibition of herpes simplex virus type 2 replication by encapsulation in liposomes.

Authors:  F C Szoka; C J Chu
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

5.  A robust and quantitative method for tracking liposome contents after intravenous administration.

Authors:  Aditya G Kohli; Heidi M Kieler-Ferguson; Darren Chan; Francis C Szoka
Journal:  J Control Release       Date:  2013-12-22       Impact factor: 9.776

6.  Retention of topical liposomal formulations on the cornea.

Authors:  T A McCalden; M Levy
Journal:  Experientia       Date:  1990-07-15

7.  Tumour targeting with antibody-coupled liposomes: failure to achieve accumulation in xenografts and spontaneous liver metastases.

Authors:  S Matzku; H Krempel; H P Weckenmann; V Schirrmacher; H Sinn; H Stricker
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

8.  Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.

Authors:  F C Szoka; D Milholland; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

Review 9.  Recent Developments of Liposomes as Nanocarriers for Theranostic Applications.

Authors:  Hang Xing; Kevin Hwang; Yi Lu
Journal:  Theranostics       Date:  2016-06-15       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.